Cargando…

Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report

Regorafenib has been demonstrated to prolong survival in patients with metastatic colorectal cancer refractory to standard chemotherapy. However, overall survival is limited to 2.5 months. The present report describes a unique case of metastatic colon cancer, which showed a complete response to rego...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baik, Hyungjoo, Lee, Hee Ju, Park, Jueun, Park, Ha Young, Park, Jinyoung, Lee, Sunseong, Bae, Ki Beom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506641/ https://www.ncbi.nlm.nih.gov/pubmed/34650810 http://dx.doi.org/10.3892/mco.2021.2405

Ejemplares similares

Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
por: Lee, Min-Sang, et al.
Publicado: (2020)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
por: Yoon, Sang Eun, et al.
Publicado: (2018)

The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer
por: Yoon, Sang Eun, et al.
Publicado: (2019)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer
por: Lim, Yoojoo, et al.
Publicado: (2015)

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer
por: Lee, Dae-Won, et al.
Publicado: (2023)

Fatal Acute Liver Failure as a Consequence of Regorafenib Treatment in a Metastatic Colon Cancer
por: Béchade, Dominique, et al.
Publicado: (2017)

Regorafenib prevents the development of emphysema in a murine elastase model
por: Oh, Kwangseok, et al.
Publicado: (2023)

Real-world experience of safety and effectiveness of regorafenib for treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma: a post-marketing surveillance study in Korea
por: Beom, Seung-Hoon, et al.
Publicado: (2022)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Cholangiocarcinoma in choledochal cyst after cystoenterostomy: how a mistreated choledochal cyst can progress to malignancy
por: Baik, HyungJoo, et al.
Publicado: (2016)

Regorafenib Regulates AD Pathology, Neuroinflammation, and Dendritic Spinogenesis in Cells and a Mouse Model of AD
por: Han, Kyung-Min, et al.
Publicado: (2020)

Colorectal Carcinogenesis: MSI-H Versus MSI-L
por: Pawlik, Timothy M., et al.
Publicado: (2004)

Defining regorafenib as a senomorphic drug: therapeutic potential in the age-related lung disease emphysema
por: Park, Jung-Jin, et al.
Publicado: (2023)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
por: Amram, Marie-Laure, et al.
Publicado: (2017)

Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
por: Ricci, Vincenzo, et al.
Publicado: (2020)

Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer
por: Karasic, Thomas B, et al.
Publicado: (2022)

Evaluation of Factors Predicting the Effectiveness of Regorafenib in the Treatment of Metastatic Colorectal Cancer
por: Ebinç, Senar, et al.
Publicado: (2022)

Clinical outcomes of complete cytoreduction with concurrent liver resection followed by hyperthermic intraperitoneal chemotherapy for synchronous peritoneal and liver metastatic colorectal cancer
por: Jeon, Youngbae, et al.
Publicado: (2019)

Advanced Colonic Neoplasia at Follow-up Colonoscopy According to Risk Components and Adenoma Location at Index Colonoscopy: A Retrospective Study of 1,974 Asymptomatic Koreans
por: Baik, Su Jung, et al.
Publicado: (2017)

The complete chloroplast genome of Typhonium giganteum (Araceae)
por: Kim, Jinhyuk, et al.
Publicado: (2020)

The complete chloroplast genome of Sinomenium acutum (Menispermaceae)
por: Kim, Jinhyuk, et al.
Publicado: (2020)

Cancer-specific functional profiling in microsatellite-unstable (MSI) colon and endometrial cancers using combined differentially expressed genes and biclustering analysis
por: Na, Woong, et al.
Publicado: (2023)

Pathological Complete Response Following Neoadjuvant Tislelizumab Monotherapy in Treatment-Naive Locally Advanced, MMR-Deficient/MSI-High Ascending Colon Cancer: A Case Report
por: Hei, Yue, et al.
Publicado: (2022)

Is prognosis uniformly excellent in patients with stage II MSI-high colon cancer?
por: Wang, Jane, et al.
Publicado: (2022)

Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
por: Takigawa, Hidehiko, et al.
Publicado: (2016)

Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond
por: Park, Robin, et al.
Publicado: (2021)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
por: Khan, Gazala, et al.
Publicado: (2014)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer
por: Prager, Gerald, et al.
Publicado: (2017)

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib
por: Arai, Hiroyuki, et al.
Publicado: (2017)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
por: Aljubran, Ali, et al.
Publicado: (2019)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
por: Yoshino, Kenji, et al.
Publicado: (2017)

Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
por: Xu, Donghao, et al.
Publicado: (2022)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nfmju4fr33fa3b6v9pch75t01t